EUVIMEDEUVIMED entdecken
Crossref

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI

Benjamin Douglas Liu iD, Donovan Veccia, Yan Sun, Gengqing Song

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Benjamin Douglas Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Body Mass Index, Obesity, Gastrointestinal Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We performed a re‐analysis of the gastrointestinal risks of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP‐1 RA n = 8792; Bupropion‐naltrexone n = 8792) after accounting for initial BMI. GLP‐1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19–4.46) and biliary disease (aHR 1.27; 95% CI 0.96–1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13–2.70). Semaglutide conferred superior weight loss but increased biliary risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsBody Mass IndexObesityGastrointestinal DiseasesHypoglycemic AgentsHumansFemaleMaleMiddle AgedAdultGlucagon-Like PeptidesRisk FactorsAgedGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

biliary diseasebupropion‐naltrexoneglucagon‐like Peptide‐1 receptor agonistpancreatitisweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID-Profile: Benjamin Douglas Liu

Zitieren

APA

Liu, B. D., Veccia, D., Sun, Y., & Song, G. (2025). Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70190

Vancouver

Liu BD, Veccia D, Sun Y, Song G. Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70190

BibTeX
@article{Liu2025,
  author = {Liu, Benjamin Douglas and Veccia, Donovan and Sun, Yan and Song, Gengqing},
  title = {Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70190}
}
Kostenlos starten →